Product Description
AKT1, also known as protein kinase B alpha (PKBα), is a member of the serine/threonine kinase family and a central component of the PI3K/AKT signaling pathway, which plays a pivotal role in cell survival, proliferation, metabolism, and apoptosis. AKT1 is activated downstream of receptor tyrosine kinases (RTKs) and GPCRs through phosphatidylinositol 3‑kinase (PI3K)-dependent membrane recruitment and phosphorylation. Beyond its essential physiological functions, dysregulation of AKT1—including activating mutations (such as E17K), gene amplification, and aberrant upstream signaling—is frequently observed in a wide range of human cancers, contributing to tumor growth, treatment resistance, and poor prognosis. These features have established AKT1 as a highly validated and strategically important target for cancer therapy and drug discovery.
Screeningbio’s ATK1 Kinase Assay Kit provides a robust, sensitive, and high-throughput platform for quantifying ATK1 kinase activity and evaluating the potency of tyrosine kinase inhibitors (TKIs).
This kit utilizes the ADP-Glo Kinase Assay platform, a luminescent technology that measures the amount of ADP produced during the kinase reaction.
The assay is performed in two distinct steps:
Kinase Reaction: ATK1 catalyzes the transfer of a phosphate group from ATP to a specific substrate, resulting in the production of phosphorylated substrate and ADP.
ADP-Glo™ Reagent Addition: After the kinase reaction, the ADP-Glo™ Reagent is added to terminate the reaction and deplete any remaining unreacted ATP.
Kinase Detection: The Kinase Detection Reagent is added to simultaneously convert the produced ADP back into ATP, which is then used by luciferase to generate a luminescent signal.
The light intensity produced is directly proportional to the ADP concentration and, consequently, to the enzymatic activity of the ATK1 kinase.
Data